Summit X LLC’s 9 Meters Biopharma NMTR Stock Holding History

Summit X LLC’s Portfolio NMTR Stock Details NMTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10	Closed	-$2K	–	453
2020 Q2	$2K	Sell	10 -490	-98%	-$5.53K	﹤0.01%	212
2020 Q1	$1K	Buy	+500	New	+$6.27K	﹤0.01%	198

Other funds holding NMTR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

ODFS

O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

Summit X LLC's NMTR Position: Q4 2022 in Review

Summit X LLC sold out of 9 Meters Biopharma (NMTR) in Q4 2022, closing a stake of 640 shares — an estimated $1K sold.

Summit X LLC first reported a position in NMTR in Q3 2019 and held it in 13 quarters. The position peaked at $24K in Q1 2021. 42 funds tracked by Wall St. Rank hold NMTR as of Q4 2022.

Summit X LLC reported no remaining 9 Meters Biopharma position as of Q4 2022 after selling out during the quarter.
Summit X LLC sold 640 9 Meters Biopharma shares in Q4 2022, an estimated $1K.
Summit X LLC first reported a position in 9 Meters Biopharma in Q3 2019 and held it in 13 quarters.
Summit X LLC's 9 Meters Biopharma position peaked at $24K in Q1 2021.
42 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q4 2022.

Based on Summit X LLC's 13F filing for Q4 2022, filed 3 Feb 2023.